Oramed Pharmaceuticals ORMP
NASDAQ ORMP
$4.49 +0.01 (+0.22%)
At close: Oct 2, 2026 · 4:00 PM EDT

Oramed Pharmaceuticals (ORMP) Gains from Equity Investments (2020)

Updated

Oramed Pharmaceuticals' Gains from Equity Investments came in at $1 million for Q1 2021.

Analysis

Oramed Pharmaceuticals (ORMP) Gains from Equity Investments (2020) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Oramed Pharmaceuticals 185.50 Mn 185.50 Mn -
Historic Data

Historic Data

Download Data
DateValue
Nov 30, 2020 1.00 Mn
API Access

Oramed Pharmaceuticals Gains from Equity Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-equity-investments&ticker=ORMP&period=max&api_key=YOUR_API_KEY